IMRA - the odds of failure for early bioscience stories has always been high and there are now even more "pre" preclinical publicly traded via SPACs and PIPEs.
Today’s $IMRA setback made me curious so I checked:
There are 163 biotech/drug stocks on U.S. exchanges (NYSE, AMEX, Nasdaq) valued at $50M or lower, per a Finviz screen.
288 bio/drug stocks with market caps $100M or less.
— Adam Feuerstein ✡️ (@adamfeuerstein) April 5, 2022
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.